Trial Profile

Clinical trial of BN301 (STRO-001) in patients with hematologic malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs STRO 001 (Primary)
Indications B-cell lymphoma; Haematological malignancies; Non-Hodgkin's lymphoma
Focus Adverse reactions

15 May 2023 According to a Sutro Biopharma media release, the company plans to leverage the clinical data produced by its partner BioNova Pharma (BioNova) in Greater China to make future prioritization decisions regarding further clinical development.
30 Mar 2023 According to a Sutro Biopharma media release, In February 2023, BioNova announced that the first patient had been dosed in this study.
30 Mar 2023 According to a Sutro Biopharma media release, Status changed from planning to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com